My ePortfolio Register   

Adjuvant trastuzumab did not improve outcomes for patients with HER2-low breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.17
Views: 113

Dr Louis Fehrenbacher - Kaiser Permanente Vallejo Medical Center, California, USA

Dr Fehrenbacher speaks at a SABCS 2017 press session about data from the randomised, phase III NSABP-B-47 clinical trial.

Adding trastuzumab (Herceptin) to standard adjuvant chemotherapy did not improve invasive disease–free survival for patients with early-stage breast cancer found to have low levels of HER2, as defined as immunohistochemistry (IHC) 1 or 2 and/or in situ hybridization (ISH) negative.

Watch the video interview for more.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence